115 related articles for article (PubMed ID: 28767374)
21. MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.
Bustos MA; Ono S; Marzese DM; Oyama T; Iida Y; Cheung G; Nelson N; Hsu SC; Yu Q; Hoon DSB
J Invest Dermatol; 2017 Sep; 137(9):1955-1964. PubMed ID: 28526299
[TBL] [Abstract][Full Text] [Related]
22. Comparative analysis of melanoma deregulated miRNAs in the medaka and Xiphophorus pigment cell cancer models.
Mishra RR; Kneitz S; Schartl M
Comp Biochem Physiol C Toxicol Pharmacol; 2014 Jun; 163():64-76. PubMed ID: 24462553
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors.
Pinto R; Strippoli S; De Summa S; Albano A; Azzariti A; Guida G; Popescu O; Lorusso V; Guida M; Tommasi S
Expert Opin Ther Targets; 2015; 19(8):1027-35. PubMed ID: 26156293
[TBL] [Abstract][Full Text] [Related]
24. MED27 promotes melanoma growth by targeting AKT/MAPK and NF-κB/iNOS signaling pathways.
Tang R; Xu X; Yang W; Yu W; Hou S; Xuan Y; Tang Z; Zhao S; Chen Y; Xiao X; Huang W; Guo W; Li M; Deng W
Cancer Lett; 2016 Apr; 373(1):77-87. PubMed ID: 26797421
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D.
Georgantas RW; Streicher K; Luo X; Greenlees L; Zhu W; Liu Z; Brohawn P; Morehouse C; Higgs BW; Richman L; Jallal B; Yao Y; Ranade K
Pigment Cell Melanoma Res; 2014 Mar; 27(2):275-86. PubMed ID: 24289491
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of miR-138 in patients with malignant melanoma through targeting of PDK1 in the PI3K/AKT autophagy signaling pathway.
Meng F; Zhang Y; Li X; Wang J; Wang Z
Oncol Rep; 2017 Sep; 38(3):1655-1662. PubMed ID: 28731179
[TBL] [Abstract][Full Text] [Related]
27. Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma.
Jiang CC; Croft A; Tseng HY; Guo ST; Jin L; Hersey P; Zhang XD
Oncogene; 2014 May; 33(20):2577-88. PubMed ID: 23770856
[TBL] [Abstract][Full Text] [Related]
28. Deep sequencing analysis of microRNA expression in human melanocyte and melanoma cell lines.
Ding N; Wang S; Yang Q; Li Y; Cheng H; Wang J; Wang D; Deng Y; Yang Y; Hu S; Zhao H; Fang X
Gene; 2015 Nov; 572(1):135-145. PubMed ID: 26164755
[TBL] [Abstract][Full Text] [Related]
29. miR-425 inhibits melanoma metastasis through repression of PI3K-Akt pathway by targeting IGF-1.
Liu P; Hu Y; Ma L; Du M; Xia L; Hu Z
Biomed Pharmacother; 2015 Oct; 75():51-7. PubMed ID: 26463631
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-365 Inhibits Cell Growth and Promotes Apoptosis in Melanoma by Targeting BCL2 and Cyclin D1 (CCND1).
Zhu Y; Wen X; Zhao P
Med Sci Monit; 2018 Jun; 24():3679-3692. PubMed ID: 29858490
[TBL] [Abstract][Full Text] [Related]
31. AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy.
Puig-Butille JA; Vinyals A; Ferreres JR; Aguilera P; Cabré E; Tell-Martí G; Marcoval J; Mateo F; Palomero L; Badenas C; Piulats JM; Malvehy J; Pujana MA; Puig S; Fabra À
J Invest Dermatol; 2017 Jun; 137(6):1297-1310. PubMed ID: 28188776
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Lim SY; Menzies AM; Rizos H
Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-sequencing data analyzing melanoma development and progression.
Linck L; Liebig J; Völler D; Eichner N; Lehmann G; Meister G; Bosserhoff A
Exp Mol Pathol; 2018 Dec; 105(3):371-379. PubMed ID: 30414979
[TBL] [Abstract][Full Text] [Related]
34. Ultraviolet radiation-induced differential microRNA expression in the skin of hairless SKH1 mice, a widely used mouse model for dermatology research.
Singh A; Willems E; Singh A; Ong IM; Verma AK
Oncotarget; 2016 Dec; 7(51):84924-84937. PubMed ID: 27793049
[TBL] [Abstract][Full Text] [Related]
35. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
[TBL] [Abstract][Full Text] [Related]
36. The role of microRNAs in melanoma.
Luo C; Weber CE; Osen W; Bosserhoff AK; Eichmüller SB
Eur J Cell Biol; 2014; 93(1-2):11-22. PubMed ID: 24602414
[TBL] [Abstract][Full Text] [Related]
37. Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy.
Dantonio PM; Klein MO; Freire MRVB; Araujo CN; Chiacetti AC; Correa RG
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30166456
[TBL] [Abstract][Full Text] [Related]
38. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
39. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
40. Targeting drivers of melanoma with synthetic small molecules and phytochemicals.
Strickland LR; Pal HC; Elmets CA; Afaq F
Cancer Lett; 2015 Apr; 359(1):20-35. PubMed ID: 25597784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
